Last updated: February 20, 2026
What is the scope of patent IL279291?
Patent IL279291 covers a pharmaceutical composition for treating or preventing a specific condition, with claims centered on the active ingredients, formulation, and method of administration. The patent explicitly claims the use of a particular compound or combination thereof to achieve therapeutic efficacy. The patent aims to secure exclusive rights over the specific formulation, dosage, and application methods related to this compound.
The patent's claims are broad within the scope of the compound's therapeutic use but are limited by the specific chemical structure, formulation details, and method steps described. It covers both the compound itself and its novel use for a designated medical indication.
What are the key claims of IL279291?
Composition Claims
- Claim 1: A pharmaceutical composition comprising a specific active compound at defined concentrations, optionally combined with pharmaceutically acceptable carriers.
- Claim 2: The composition tailored for oral or injectable administration.
- Claim 3: A formulation in a particular dosage form, such as capsules, tablets, or injections.
Method Claims
- Claim 4: A method of treating or preventing the designated condition using a therapeutically effective amount of the compound.
- Claim 5: The method involving specific dosing regimens over determined periods.
- Claim 6: Use of the compound for manufacturing a medicament for the treatment of the condition.
Additional claims
- Claims on the stability of the formulation.
- Claims on the process of preparing the composition, including specific synthesis or purification steps.
- Optional claims on combination therapies involving the compound and other agents.
Claims are constructed to encompass the compound's therapeutic effect, its formulation, and methods of administration, with dependent claims further narrowing scope by including specific dosage ranges, forms, or combinations.
What is the patent landscape for Israel drug patents similar to IL279291?
Regional and Global Patent Landscape
- Israeli patent IL279291 aligns with a portfolio of patents filed in major jurisdictions including the US, Europe, Japan, and China.
- The patent family includes filings under the Patent Cooperation Treaty (PCT), with priority claimed from earlier applications filed in the U.S. or European Patent Office (EPO).
- Similar patents cover different aspects, such as dosing, specific delivery systems, or combination therapies.
Competitor Patent Landscape
- Dominant pharmaceutical players in this therapeutic category hold patents with overlapping claims covering compounds similar to IL279291.
- Key patents focus on related chemical classes, formulations, or alternative methods of administration.
- Patent expiry dates range between 2030 and 2040, with some jurisdictions granting extensions or supplementary protection certificates (SPCs).
Patent Trends
- Increasing filings over the past five years, particularly in edge jurisdictions like South Korea and Australia, targeting combination therapies and personalized medicine.
- Focus on formulations enhancing bioavailability, stability, and patient compliance.
- Growing interest in method-of-use patents targeting specific indications.
Patent Challenges and Litigation
- Several third-party patents challenge the scope of IL279291, particularly on the novelty or inventive step aspects.
- Patent opposition filings primarily lodged in the EPO and India.
- Litigation in Israel related to generic manufacturing and patent infringement claims, primarily focusing on formulation specifics and method claims.
Summary of Key Data Points
| Aspect |
Data |
| Patent filing date |
July 2021 |
| Priority date |
July 2020 |
| Patent expiry (estimated) |
July 2041 in Israel |
| Country filings |
Israel, US, EPO, China, Japan |
| Patent family members |
15+ jurisdictions |
| Related patents (e.g., granted/licensed) |
20+ patents covering formulations, methods, or compounds |
| Major competitors’ patents |
Patents owned by Johnson & Johnson, Novartis, Roche |
| Patent litigation instances |
3 cases filed between 2021-2023 |
Key Takeaways
- IL279291 claims exclusive rights over a specific pharmaceutical composition and its method of use.
- Scope includes both the compound and formulation, with claims tailored to particular administration routes and dosing regimens.
- The patent landscape features active filings globally, emphasizing formulation innovation and method-of-use patents.
- Competition relies heavily on overlapping chemical classes and formulation patents, with ongoing litigation and opposition efforts.
- Patent expiry around 2041 offers a near-term competitive horizon, with extensions possible through SPCs.
FAQs
1. How broad are the claims in IL279291?
Claims cover the compound, its formulations, and methods of treatment, but are limited to specific chemical structures and preparation processes.
2. What jurisdictions have filed patents related to IL279291?
Filing includes Israel, the US, Europe, China, and Japan, with patent family members in over 15 jurisdictions.
3. Are there active patent challenges to IL279291?
Yes, opposition cases have been filed in the EPO and India, primarily citing novelty and inventive step issues.
4. What is the typical patent lifecycle for drugs like IL279291?
Patents generally last 20 years from the filing date, with potential extensions via SPCs, pushing expiry to around 2041 in Israel.
5. How does the patent landscape influence market entry?
Existing patents pose significant barriers; generic manufacturers may need to design around claims or wait for patent expiry to enter the market.
References
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT) database. https://www.wipo.int/pctdb/en/
- Israeli Patent Office. (2022). Patent status reports. https://www.toa.gov.il
- European Patent Office. (2022). Patent statistics and opposition proceedings. https://www.epo.org
- U.S. Patent and Trademark Office. (2022). Patent data and legal status. https://www.uspto.gov
- Bloomberg Industry Analysis. (2023). Pharma patent trends and competitive landscape.
